Path ID: DB00674_MESH_D000544_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D005702 | galantamine | Drug |
| UniProt:P22303 | Acetylcholinesterase | Protein |
| GO:0006581 | acetylcholine catabolic process | BiologicalProcess |
| CHEBI:15355 | acetylcholine | ChemicalSubstance |
| HP:0100543 | Cognitive impairment | PhenotypicFeature |
| MESH:D000544 | Alzheimer’s disease | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Galantamine | DECREASES ACTIVITY OF | Acetylcholinesterase |
| Acetylcholinesterase | POSITIVELY REGULATES | Acetylcholine Catabolic Process |
| Acetylcholine Catabolic Process | DECREASES ABUNDANCE OF | Acetylcholine |
| Acetylcholine | NEGATIVELY CORRELATED WITH | Cognitive Impairment |
| Cognitive Impairment | MANIFESTATION OF | Alzheimer’S Disease |
Comment: The cause of cognitive impairment in Alzheimer’s Disease is not fully understood. It’s khown that acetylcholine producing neurons degenerate and it’s believed that this cholinergic loss is correlated with cognitive impairment and a density of amyloid plaques (https://pubchem.ncbi.nlm.nih.gov/compound/9651#section=Mechanism-of-Action).
Reference: